GMAB

Announcements

Nothing here yet

Daily updates

• Genmab and AbbVie's Epkinly plus standard chemotherapy nearly halved the risk of disease progression or death versus chemotherapy alone in a Phase 3 trial of newly diagnosed lymphoma patients.Oct 6, 2026

FDA designations

• Genmab Receives FDA Breakthrough Therapy Designation for Rina-S® in Advanced Endometrial CancerAug 26, 2025

News

• Genmab and AbbVie report statistically significant improvement in progression-free survival with epcoritamab plus R-CHOP in newly diagnosed DLBCLOct 5, 2026
• Genmab reports Phase 2 RAINFOL-01 results for rinatabart sesutecan (Rina-S) showing durable and clinically meaningful responses in platinum-resistant ovarian cancerOct 4, 2026
• Genmab announces Phase 1b/2 EPCORE® CLL-1 data highlighting epcoritamab potential in Richter transformationDec 9, 2025
• Genmab receives FDA breakthrough therapy designation for Rinatabart Sesutecan (Rina-S®) in advanced endometrial cancerAug 26, 2025
• Genmab announces Phase 3 EPCORE® FL-1 trial met dual primary endpoints in relapsed/refractory follicular lymphoma patientsAug 8, 2025